In today’s recent session, 2.39 million shares of the Novo Nordisk ADR (NYSE:NVO) have been traded, and its beta is 0.66. Most recently the company’s share price was $77.84, and it changed around -$1.99 or -2.49% from the last close, which brings the market valuation of the company to $262.02B. NVO at last check was trading at a discount to its 52-week high of $148.15, offering almost -90.33% off that amount. The share price’s 52-week low was $57.00, which indicates that the recent value has risen by an impressive 26.77% since then.
Novo Nordisk ADR stock received a consensus recommendation rating of Hold, based on a mean score of 2.06. If we narrow it down even further, the data shows that 1 out of 13 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 5 recommended NVO as a Hold, whereas 4 deemed it a Buy, and 1 rated it as Underweight. Novo Nordisk ADR is expected to report earnings per share of 5.92 for the current quarter.
Novo Nordisk ADR (NYSE:NVO) trade information
Instantly NVO has been showing red trend so far today with a performance of -2.49% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 81.44 on recent trading dayincreased the stock’s daily price by 4.42%. The company’s shares are currently down -9.51% year-to-date, but still up 3.15% over the last five days. On the other hand, Novo Nordisk ADR (NYSE:NVO) is 17.67% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $158, which translates to bulls needing to increase their stock price by 50.73% from its current value. Analyst projections state that NVO is forecast to be at a low of $156 and a high of $160.
Novo Nordisk ADR (NVO) estimates and forecasts
The year-over-year growth rate is expected to be 14.62%, up from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 77.51B in revenue for the current quarter. 9 analysts expect Novo Nordisk ADR to make 83B in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 68.06B and 71.31B respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 13.88%. Forecasts for the next quarter put sales growth at 16.38%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 21.74%. Novo Nordisk ADR earnings are expected to increase by 26.29% in 2025, but the outlook is positive 18.78% per year for the next five years.
NVO Dividends
Novo Nordisk ADR’s next quarterly earnings report is expected to be released in July. The annual dividend yield of the stock is 2.13 percent and its annual dividend per share was 1.66. It is important to note, however, that the 2.13% dividend yield ratio should be regarded as a guide only, as many other factors should be taken into consideration before making any investment decision.
FMR LLC, with 0.4373% or 19.49 million shares worth $2.78 billion as of 2024-06-30, holds the second largest percentage of outstanding shares.
